Cynata Therapeutics 관리
관리 기준 확인 3/4
Cynata Therapeutics' CEO is Kilian Kelly, appointed in Jul 2023, has a tenure of 1.33 years. total yearly compensation is A$544.83K, comprised of 71.7% salary and 28.3% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth A$142.52K. The average tenure of the management team and the board of directors is 2.2 years and 4.4 years respectively.
주요 정보
Kilian Kelly
최고 경영자
AU$544.8k
총 보상
| CEO 급여 비율 | 71.7% |
| CEO 임기 | 1.3yrs |
| CEO 소유권 | 0.3% |
| 경영진 평균 재임 기간 | 2.2yrs |
| 이사회 평균 재임 기간 | 4.4yrs |
최근 관리 업데이트
Recent updates
Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Sep 21
Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?
May 29We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate
Feb 09We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow
Feb 02We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth
Sep 09Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
May 26Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Dec 31We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn
Aug 11CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | AU$545k | AU$391k | -AU$10m |
| Mar 31 2024 | n/a | n/a | -AU$12m |
| Dec 31 2023 | n/a | n/a | -AU$14m |
| Sep 30 2023 | n/a | n/a | -AU$14m |
| Jun 30 2023 | AU$413k | AU$334k | -AU$14m |
| Mar 31 2023 | n/a | n/a | -AU$12m |
| Dec 31 2022 | n/a | n/a | -AU$9m |
| Sep 30 2022 | n/a | n/a | -AU$7m |
| Jun 30 2022 | AU$499k | AU$313k | -AU$5m |
| Mar 31 2022 | n/a | n/a | -AU$5m |
| Dec 31 2021 | n/a | n/a | -AU$4m |
| Sep 30 2021 | n/a | n/a | -AU$6m |
| Jun 30 2021 | AU$737k | AU$300k | -AU$8m |
| Mar 31 2021 | n/a | n/a | -AU$7m |
| Dec 31 2020 | n/a | n/a | -AU$6m |
| Sep 30 2020 | n/a | n/a | -AU$5m |
| Jun 30 2020 | AU$472k | AU$300k | -AU$4m |
| Mar 31 2020 | n/a | n/a | -AU$6m |
| Dec 31 2019 | n/a | n/a | -AU$8m |
| Sep 30 2019 | n/a | n/a | -AU$8m |
| Jun 30 2019 | AU$449k | AU$279k | -AU$8m |
| Mar 31 2019 | n/a | n/a | -AU$7m |
| Dec 31 2018 | n/a | n/a | -AU$6m |
| Sep 30 2018 | n/a | n/a | -AU$5m |
| Jun 30 2018 | AU$357k | AU$259k | -AU$5m |
보상 대 시장: Kilian's total compensation ($USD359.84K) is about average for companies of similar size in the Australian market ($USD299.27K).
보상과 수익: Kilian's compensation has increased whilst the company is unprofitable.
CEO
Kilian Kelly
1.3yrs
테뉴어
AU$544,827
보상
Dr. Kilian Kelly has been Chief Executive Officer and Managing Director at Cynata Therapeutics Limited since July 1, 2023 and has been its Director since 2023 and had been its Chief Operating Officer since...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| MD, CEO & Director | 1.3yrs | AU$544.83k | 0.34% A$ 142.5k | |
| Chief Medical Officer | 3.1yrs | AU$398.72k | 데이터 없음 | |
| Chief Business Officer | less than a year | AU$379.02k | 데이터 없음 | |
| Company Secretary | 12.6yrs | AU$140.00k | 데이터 없음 |
2.2yrs
평균 재임 기간
경험이 풍부한 관리: CYP's management team is considered experienced (2.2 years average tenure).
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| MD, CEO & Director | 1.8yrs | AU$544.83k | 0.34% A$ 142.5k | |
| Independent Non-Executive Chairman | 5.5yrs | AU$138.77k | 0.14% A$ 59.2k | |
| Independent Non-Executive Director | 8.4yrs | AU$68.20k | 0.17% A$ 72.5k | |
| Independent Non-Executive Director | 2.2yrs | AU$81.69k | 0.064% A$ 26.7k | |
| Independent Non-Executive Director | 4.4yrs | AU$68.20k | 0.028% A$ 11.5k |
4.4yrs
평균 재임 기간
64yo
평균 연령
경험이 풍부한 이사회: CYP's board of directors are considered experienced (4.4 years average tenure).